A 62-year-old postmenopausal woman presents with a T-score of −2.8 on DEXA scan of the lumbar spine. She has no prior fragility fractures. Her serum calcium is 8.9 mg/dL (normal), phosphate 3.5 mg/dL (normal), and alkaline phosphatase 72 U/L (normal). Renal function and liver function are normal. She denies significant alcohol use and has adequate dietary calcium intake. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has osteoporosis (T-score ≤ −2.5) without prior fracture. Before initiating pharmacotherapy, it is essential to identify and correct modifiable risk factors, particularly vitamin D deficiency, which is highly prevalent in India and directly impairs bone mineralization and increases fracture risk. ## Why Vitamin D Assessment First? **Key Point:** Vitamin D deficiency must be ruled out and corrected BEFORE or CONCURRENT with bisphosphonate initiation, because: - Bisphosphonates work optimally only when vitamin D and calcium stores are adequate - Vitamin D deficiency causes secondary hyperparathyroidism, accelerating bone loss - Correction of vitamin D deficiency alone may improve bone density and reduce fracture risk - Hypocalcemia or secondary hyperparathyroidism may develop if bisphosphonates are given without adequate vitamin D ## Management Algorithm ```mermaid flowchart TD A[Osteoporosis diagnosed on DEXA]:::outcome --> B{Biochemistry normal?}:::decision B -->|Yes| C[Measure 25-OH Vitamin D]:::action C --> D{Vitamin D deficient?}:::decision D -->|Yes| E[Supplement vitamin D + calcium]:::action D -->|No| F[Proceed to pharmacotherapy]:::action E --> G[Recheck biochemistry in 6-8 weeks]:::action G --> F F --> H[Initiate bisphosphonate]:::action ``` **High-Yield:** In India, vitamin D deficiency (< 20 ng/mL) is present in 50–90% of the population, even in those with adequate sun exposure. It is the most common modifiable cause of low bone density. **Clinical Pearl:** The presence of normal serum calcium and phosphate does NOT exclude vitamin D deficiency. Many patients maintain normocalcemia through secondary hyperparathyroidism, which paradoxically worsens bone loss. ## Recommended Next Steps (in sequence) 1. Measure serum 25-hydroxyvitamin D (target > 30 ng/mL or > 75 nmol/L) 2. If deficient: supplement with vitamin D₃ 1000–2000 IU daily + elemental calcium 1000–1200 mg daily 3. Recheck biochemistry (calcium, phosphate, alkaline phosphatase) in 6–8 weeks 4. Once vitamin D replete: initiate bisphosphonate therapy [cite:Harrison 21e Ch 397]